Published in Clin Exp Immunol on February 01, 1991
Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol (1991) 1.12
IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol (1991) 1.06
Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site. Clin Exp Immunol (2001) 1.02
Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults. J Clin Invest (1998) 0.97
Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol (1995) 0.94
Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol (1998) 0.93
Antiidiotype antibody against platelet anti-GPIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients. J Exp Med (2000) 0.88
Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol (2009) 0.86
Inhibition of histone/anti-histone reactivity by histone-binding serum components; differential effect on anti-H1 versus anti-H2B antibodies. Clin Exp Immunol (1994) 0.82
Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin. Clin Exp Immunol (1994) 0.82
Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes. Autoimmunity (2012) 0.82
Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice. J Clin Immunol (1998) 0.81
Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies. Immunology (2007) 0.81
Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol (2010) 0.81
Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis. PLoS One (2011) 0.80
Pregnancy in Wegener's granulomatosis: successful treatment with intravenous immunoglobulin. Clin Rheumatol (2004) 0.80
Analysis of immunoglobulin variable region genes of a human IgM anti-myeloperoxidase antibody derived from a patient with vasculitis. Immunology (1996) 0.80
Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins. J Neuroinflammation (2015) 0.79
Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol (2005) 0.78
Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry (1994) 0.78
Anti-idiotype antibodies in immune regulation of anca associated vasculitis. Indian J Dermatol (2009) 0.76
New methods of treatment in an experimental murine model of systemic lupus erythematosus induced by idiotypic manipulation. Ann Rheum Dis (1997) 0.75
Clinical immunology. Postgrad Med J (1991) 0.75
Towards a network theory of the immune system. Ann Immunol (Paris) (1974) 16.43
Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet (1985) 10.67
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med (1988) 8.01
Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet (1987) 4.20
Association of alkaline phosphatase with an autoantigen recognised by circulating anti-neutrophil antibodies in systemic vasculitis. Lancet (1987) 2.85
Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet (1984) 2.47
Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J Clin Invest (1981) 2.24
Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A (1987) 1.49
Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol (1989) 1.46
Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev (1989) 1.35
Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest (1990) 1.20
Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol (1990) 1.02
Auto-anti-anti-DNA antibodies from SLE patients and normals. J Rheumatol (1984) 0.93
Equivalence of the mediation, confounding and suppression effect. Prev Sci (2000) 13.92
2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum (2013) 11.18
Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet (1987) 4.20
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med (1979) 3.02
Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet (1976) 3.00
Natural autoantibodies. Curr Opin Immunol (1995) 3.00
Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS (1998) 2.90
Association of alkaline phosphatase with an autoantigen recognised by circulating anti-neutrophil antibodies in systemic vasculitis. Lancet (1987) 2.85
The intermediate endpoint effect in logistic and probit regression. Clin Trials (2007) 2.67
Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet (1984) 2.47
Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med (1985) 2.46
Value of immune-complex assays in diagnosis and management. Lancet (1978) 2.39
Relapses in Wegener's granulomatosis: the role of infection. Br Med J (1980) 2.29
Defective reticuloendothelial system function in rheumatoid arthritis. Lancet (1979) 2.10
Wegener's granulomatosis: observations on 18 patients with severe renal disease. Q J Med (1983) 2.07
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS (2000) 1.97
Enhanced allergic tissue injury in Goodpasture's syndrome by intercurrent bacterial infection. Br Med J (1977) 1.92
Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol (1985) 1.91
Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet (1983) 1.87
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis (2000) 1.86
Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant (1994) 1.80
Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM (1996) 1.78
Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. J Infect Dis (2001) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet (1977) 1.71
Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) (1986) 1.65
Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS (1998) 1.62
Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med (1980) 1.57
Effect of anti-neutrophil cytoplasm autoantibodies on the intracellular calcium concentration of human neutrophils. Lab Invest (1994) 1.56
Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int (1990) 1.55
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 1.53
Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol (2000) 1.53
Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci U S A (1987) 1.49
Mapping of the region of complement receptor (CR) 1 required for Plasmodium falciparum rosetting and demonstration of the importance of CR1 in rosetting in field isolates. J Immunol (2000) 1.48
Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol (1989) 1.46
Comparative assessment of five alternative methods for CD4+ T-lymphocyte enumeration for implementation in developing countries. J Acquir Immune Defic Syndr (2001) 1.44
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med (1991) 1.44
Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM (2000) 1.44
Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol (1998) 1.43
A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Arthritis Rheum (2001) 1.43
Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies. Clin Exp Immunol (1991) 1.42
Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods (1998) 1.41
Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int (1991) 1.40
Binding sites for endotoxins (lipopolysaccharides) on human monocytes. J Immunol (1991) 1.39
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol (1995) 1.37
Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J Immunol (1991) 1.37
Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. Clin Exp Immunol (1992) 1.37
Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol (1984) 1.36
Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev (1989) 1.35
Immunohistochemical study of the C5b-9 complex of complement in human kidneys. Kidney Int (1986) 1.33
Amyloid P-component in human glomerular basement membrane. Abnormal patterns of immunofluorescent staining in glomerular disease. Lancet (1980) 1.32
Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med (1990) 1.32
Autoregulation of autoantibody synthesis in mercuric chloride nephritis in the Brown Norway rat. I. A role for T suppressor cells. Eur J Immunol (1984) 1.31
ANCA and predicting relapse in systemic vasculitis. QJM (1995) 1.29
Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin Diagn Lab Immunol (2000) 1.26
Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol (1995) 1.24
Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut (1997) 1.23
Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci U S A (1987) 1.23
Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest (1981) 1.23
Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest (1990) 1.20
Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J Infect Dis (2001) 1.20
Severe pulmonary hemorrhage and systemic vasculitis in association with circulating anti-neutrophil cytoplasm antibodies of IgM class only. Clin Nephrol (1989) 1.19
Autoimmunity in rapidly progressive glomerulonephritis. Kidney Int (1989) 1.19
Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. Proc Natl Acad Sci U S A (1995) 1.18
Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant (1991) 1.18
Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol (1990) 1.18
Vasculitis-aims of therapy. An overview. Rheumatology (Oxford) (2000) 1.17
Kinetics and pathogenicity of autoantibodies induced by mercuric chloride in the brown Norway rat. Clin Exp Immunol (1990) 1.16
Clinical and immunological evolution of oligoanuric anti-GBM nephritis treated by haemodialysis. Lancet (1986) 1.16
Antineutrophil cytoplasm antibodies in Kawasaki disease. Arch Dis Child (1989) 1.15
Clinical application of a radio-immunoassay for auto-antibodies to glomerular basement membrane. J Clin Lab Immunol (1985) 1.13
Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol (1991) 1.12
Anti-glomerular basement membrane autoantibodies in the Brown Norway rat: detection by a solid-phase radioimmunoassay. J Immunol Methods (1983) 1.11
Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis (1997) 1.11
Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol (1993) 1.11
Induction of cell-associated interleukin 1 through stimulation of the adhesion-promoting proteins LFA-1 (CD11a/CD18) and CR3 (CD11b/CD18) of human monocytes. Eur J Immunol (1990) 1.11
Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol (2001) 1.11
Intracellular potassium in diffuse proctocolitis. Lancet (1971) 1.10
C3a(C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol (1987) 1.10
Suboptimal C3b/C3bi deposition and defective yeast opsonization. I. Evidence for the absence of essential co-factor activity. Clin Exp Immunol (1985) 1.10
Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol (1998) 1.09
Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis (2000) 1.08
Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods (1996) 1.08
The self-reactive antibody repertoire of normal human serum IgM is acquired in early childhood and remains conserved throughout life. Scand J Immunol (1996) 1.08
Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells. J Virol (2001) 1.08
A single autoantigen in Goodpasture's syndrome identified by a monoclonal antibody to human glomerular basement membrane. Lab Invest (1987) 1.08
Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin Microbiol Infect (2000) 1.08
A comprehensive method to purify three major ANCA antigens: proteinase 3, myeloperoxidase and bactericidal/permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods (1996) 1.07
IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol (1991) 1.06
Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. J Immunol (1990) 1.06
Antineutrophil cytoplasm antibody in crescentic glomerulonephritis. Arch Dis Child (1988) 1.05
Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD). Clin Exp Immunol (1998) 1.05
Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab (2000) 1.04